Statement: the primary trial participants are given saracatinib PO for a maximum of 28 days.
Primary_evidence: INTERVENTION 1:    Treatment (Enzyme Inhibitor Therapy)   Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.